<DOC>
	<DOCNO>NCT00655603</DOCNO>
	<brief_summary>Incretinbased treatment patient type 2 diabetes mellitus ( T2DM ) increase interest . The incretin glucagon-like peptide-1 ( GLP-1 ) stimulate beta-cells increased secretion production insulin . Glucose sensitivity enhance , apoptosis inhibit - progression disease potentially stop . The alpha-cell also influence GLP-1 infusion lower plasmaglucose ( PG ) level patient type 1 diabetes mellitus ( T1DM ) ( C-peptide negative ) inhibition glucagon thereby decrease hepatic glucoseproduction ( HGP ) . Further Vilsboll et al prove normalization glacgonostatic effect glucose patient T2DM . As attempt elucidate glucose-intolerance patient T2DM Knop et al investigate glucagonresponse oral glucose tolerance test ( OGTT ) follow iso-glycemic clamp . He saw sufficient suppression glucagon glucose introduce intravenously suppression glucagon attenuate delayed glucose give orally . The aim study elucidate glucose intolerance . Due complex interaction mutual feed-back regulation pancreatic hormone PG level protocol include five day . All day include euglycemic-clamp , patient T2DM ( n=10 ) clamp fast PG healthy control subject ( n=10 ) . During clamp either GLP-1 alone ; GLP-1 combination somatostatin , insulin glucagon ; somatostatin , insulin glucagon infuse blood sample draw . The design study make possible isolate effect hormone . Further investigator able enlighten effect GLP-1 increase glucose turn-over induces . The essential part design hormone concentration response parameter amount glucose ( AUC ) take create euglycemic-clamp .</brief_summary>
	<brief_title>Influence Glucagon Inhibition Relation Anti-Diabetic Effect Glucagon-Like Peptide-1 ( GLP-1 ) Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Type 2 Diabetes Mellitus accord criterion WHO Normal hepatic kidney function No overt diabetic complication Treatment insulin glitazones Informed consent BMI &lt; 23 BMI &gt; 35 HbA1c &gt; 10 % Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>GLP-1</keyword>
	<keyword>Glucagon secretion</keyword>
	<keyword>Glucose turn-over</keyword>
</DOC>